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Molecular communication at the host-parasite interface
The persistence of helminth parasites in their mammalian hosts has been ascribed to their 24 striking ability to manipulate host immune responses. Many helminths are obligate blood 25 feeders and can deliver secreted molecules into the bloodstream where they exert an 26 immunosuppressive activity on the host immune system [1] . Other molecules are secreted 27 from the gut, excretory pores and surface cuticle/tegument into the local microenvironment, 28 often the host intestine [2] [3] [4] . For many years the paucity of material made these secretions 29 extremely difficult to analyse but the application of mass spectrometry-based proteomics 30 techniques has allowed a detailed understanding of the type and abundance of the various 31 proteins present in soluble helminth secretions (reviewed in [5] ). However, until quite 32 recently the contribution of extracellular vesicles (EVs; see glossary) to helminth secretomes 33 has been overlooked. 34 EVs are small membrane-bound structures that are shed by most cell types. Although 35 once considered to act solely as a cellular waste disposal system [6] , EVs are now recognised 36 as important mediators of cell-cell communication by transferring a range of effector 37 molecules including proteins, lipids, mRNA, microRNA and other non-coding RNA species. 38 Variously described as exosomes or microvesicles (MVs) depending on their composition, 39 size and mode of biogenesis (see below), EVs not only perform a variety of roles in the 40 maintenance of normal physiology but also participate in pathological settings, notably in 41 tumour progression [7] [8] [9] . A growing number of studies have also shown that parasite-derived 42 EVs play an important role during infection and pathogenesis [10] . Although most of these 43 studies have focused on profiling the molecular cargo packaged into parasite EVs, they have 44 provided a valuable first insight into the putative mechanism(s) used by parasites for EV 45 biogenesis and release. Here, we will briefly summarise the current understanding of EV reported that centre around several members of the tetraspanin family [16] or that require the 62 generation of ceramide by neutral sphingomyelinase [17] . In this respect, Colombo et al. [18] 63 proposed four molecular machineries involved in ILV formation: (1) the ESCRT pathway;
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(2) the lipid pathway primarily involving the lipid hydrolases neutral sphingomyelinase and 65 phospholipase D2; (3) the tetraspanins route where CD63 plays a principal role; and (4) a 66 hybrid mechanism combining elements of all the former machineries together. The 67 subsequent fusion of MVBs with the plasma membrane is dependent on small GTPases 68 including Ral-1, Rab8b, Rab11, Rab27a and Rab27b and the Rab effectors otoferlin and 69 synaptotagmin-like protein [19] [20] [21] [22] . Microvesicles (MVs) are larger than exosomes (diameter 100-1000 nm) and originate 71 by direct budding from the plasma membrane in response to a variety of external stimuli 72 which generally lead to elevated intracellular Ca 2+ levels and cytoskeleton-driven membrane 73 remodelling [23, 24] . This Ca 2+ signalling cascade activates scramblase that is responsible for 74 the translocation of phosphatidylserine to the outer leaflet of the plasma membrane. The 75 resulting membrane asymmetry is thought to drive localised curvature of the plasma 76 membrane. MV budding is driven further by the rearrangement of the actin cytoskeleton 77 conducted by calpain [25] . Many studies suggest that small GTPases, such as ARF6, play a 78 key role in MV formation by indirectly activating proteases in response to the activation of 79 the extracellular signal-regulated kinase (ERK) [24] . Although the final abscission 80 mechanism of the MV is not fully understood, the late ESCRT component VPS4 is likely to 81 be involved in the same way that it drives abscission of the budding ILVs into the MVB EVs as potential targets for anti-parasite therapy 88 Several studies have described the modulatory effects of parasite-derived EVs on the host 89 immune system [28] [29] [30] released by mammalian cells (Table 1) . Indeed, suppressing EV production to inhibit their 96 effect in disease is an emerging therapeutic strategy that has yielded impressive results, 97 notably in cancer therapy (reviewed in [8] ). In the same vein, parasite EV biogenesis 98 pathways might be an attractive therapeutic target if selective inhibitors could be identified.
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Disrupting the packaging, biogenesis and/or release of parasite EVs would prevent the 100 delivery of a plethora of protein or small RNA immunomodulators to host cells; thus, 101 allowing the host to mount an effective immune response against the parasite. Silencing of a 102 range of orthologues of molecules that function at different stages of EV biogenesis pathways 103 in mammalians cells led to varied aberrant phenotypes in Caenorhabditis elegans (Table 1) .
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Whilst the direct impact on EV production was not assessed for all of these targets, MVBs 105 accumulated below the cuticle layer (and did not fuse with the plasma membrane) when the 106 vATPase V0 subunit and GTPase Ral-1 were mutated or silenced [22, 45] . The challenge now 107 is to determine how silencing EV biogenesis components in parasitic helminths impacts their 108 ability to establish infection and avoid the host immune response. For instance, silencing 109 syntenin (involved in ILV formation and cargo sorting) had no effect on the ability of 110 schistosomulae and adult schistosomes to survive in vitro culture however their ability to 111 persist in mammalian hosts was not investigated [46] . 114 To date, much of our understanding of EV biogenesis in helminths comes from studies on the 115 liver fluke, Fasciola hepatica. A detailed proteomics analysis of its secretome showed that F. 116 hepatica releases at least two major sub-populations of EVs that differ according to size, suggesting that Fasciola secretes bona fide exosomes. In support of this, mass spectrometry 121 data strongly suggests an endosomal origin of the smaller secreted vesicles; up to ten proteins 122 from the ESCRT pathway were found associated with the vesicles. These included members 123 of the ESCRT-III complex and the Vps4 ATPase responsible for ILV budding and abscission 124 respectively as well as the ESCRT-associated proteins ALIX and syntenin [47] . independent pathways in the production of exosome-like vesicles in F. hepatica, as has been 182 described in other cell types [52] . In contrast, the larger Fasciola EVs were shown to be 183 specifically enriched with the inactive 37 kDa cathepsin L zymogen and may originate from 184 the specialised secretory cells that line the parasite gastrodermus [47] . Our preliminary 185 biochemical characterisation of these EVs suggest they are distinct from the smaller 186 exosome-like vesicles with respect to their cargo molecules. Data pertaining to their 187 mechanism of biogenesis is currently lacking, although MVBs have not been described in the 188 parasite gastrodermal cells. One possibility is the breakdown of the long finger-like 189 membrane-bound lamellae, which extend from the gastrodermal cells into the gut lumen, to 190 release free EVs. A similar mechanism has been described in the protozoan parasite, 
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Exosome biogenesis in helminthsinsights from Fasciola hepatica
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The mechanism of bleb formation in helminths has yet to be determined, but it is 214 thought to be a calcium-dependent process [63, 64] . MVs also bud directly from the plasma 215 membrane in response to raised intracellular Ca 2+ levels [65] . Given these biochemical and 216 structural similarities, it is conceivable that parasite blebs are formed using the same  Transcriptomics and proteomics profiling has identified a range of immunomodulatory cargo molecules packaged into these but has also begun to shed light on the mechanisms used by helminths to generate and release EVs into the host microenvironment.
 Although technically challenging, selective inhibition of parasite EV biogenesis pathways would prevent the delivery of a range of immunomodulators to host cells and tip the immune balance in favour of parasite elimination.
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Outstanding questions
 What mechanisms/pathways are used by helminths to produce and export EVs?
 Are these pathways novel or distinct from those used by mammalian cells?
 Are helminth EVs secreted constitutively or in response to stress?
 Do drug-induced MVs/blebs contribute to mechanisms of drug resistance in parasites?
 Are parasite-derived EVs essential for survival in the mammalian host?
 Can selective inhibitors of key "checkpoints" in parasite EV biogenesis pathways be developed? 
